

DAFTAR PUSTAKA

- Adam RAT., Krissat J., Bralet M , Paule B., Giacchetti S, et al. 2006. Is Liver Resection Justified for Patients with Hepatic Metastases from Breast Cancer. *Ann Surg*, 244(6), 897-907.
- Alexander HR., Berlin JM., G In Devita VT., Lawrence TS., SA (ed). 2008. *Metastatic Cancer to The Liver, Cancer Principles & Practice of Onkology*. Philadelphia: Lippincott Williams & Wilkins.
- Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. 2018. Metastatic and triple-negative breast cancer: challenges and treatment options. *Drug Deliv Transl Res*, 8(5):1483-1507.
- American Cancer Society. 2019. *Breast Cancer*. Atlanta : American Cancer Society.
- American Cancer Society. 2021. *Cancer facts and Figure*. Atlanta : American Cancer Society.
- Ardhiansyah, Azril Okta. 2019. *Surgery Mapping 2: Breast Cancer*. Airlangga University Press. ISBN 6024731930, 9786024731939.
- Arslan N., Serdar M., Deveci S., Ozturk B., Narrin Y., Ilgan S. 2000. Use of CA 15-3, CEA and Prolactin For The Primary Diagnosis of Breast Cancer and Correlation with The prognostic Factors at the time of initial diagnosis. *NCBI. Ann Nucl Med*, 14(5): 395-9.
- Atalay C. 2008. Are CA 15-3, CEA and CA 125 Predictors for Lymphatic and Vascular Spread in Breast Cancer, *Erciyas Tip Dergisi. Erciyas Medical Journal*, 30(4): 218-224.
- Ayman SMD., Abraham J., MD FACP. 2008. Role of Tumor Markers and Circulating Tumor Cells in the Management of Breast Cancer. *Cancer Network Podcast* :1-3.
- Badan Litbangkes. 2019. *Beban Kanker Indonesia*. Jakarta. Kementerian Kesehatan Republik Indonesia.
- z-Sloan JS., S.A., Davis FG. 2004. Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Area Cancer Surveillance System. *J Clin Oncol*, 22(14), 2865-2872.



- Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. 2015. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. *TLancet Oncology*;16:1380-8.
- Benjamin J Swanson, Michael A Hollingsworth. Mucin in Cancer: Protection and Control of the Cell Surface, *Nature Review*, January 2004, Vol 4: 45-60.
- Bland KI., Copeland EM. Editors. 2009. *The Breast Comprehensive Management of Benign and Malignant Diseases*. Philadelphia : WB Saunders company.
- Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, ESMO Guidelines Committee. 2019. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 30(10):1674.
- Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ. 2015. Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. *Clin Radiol*, 70(1):1-10.
- Compton., Carolyn C., Byrd., David R., Garcia-Aguilar., Julio. 2012. *AJCC Cancer Staging Atlas Second Edition*. *Springer Science Business Media LLC*, 32 : 419-440.
- Corbeau, I., Jacot, W., & Guiu, S. (2020). Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: A systematic review. *Cancers*, 12(4). <https://doi.org/10.3390/cancers12040958>
- Dawood S., Broglio KEF., et al. 2009. Survival Among Women With Triple Receptor-Negative Breast Cancer and Brain Metastasis. *(J).Ann Oncol*, 20(4), 621-627.
- Desen. W. 2008. *Buku Ajar Onkologi Klinis*, edisi 2. Jakarta: Balai Penerbitas Kedokteran Universitas Indonesia (p.365-383).



- Dorit Laessig., Dorothea Nagel., Volker Heinemann. 2007. Importance of CEA and CA15-3 during Disease Progression in Metastatic Breast Cancer Patients. *Anticancer Research*, 27: 1963-1968.
- Duffy MJ. 1999. CA 15-3 and related mucins as circulating markers in breast cancer. *Biochem* 36 :574-586.
- Duffy MJ., Duggan C., Keane R., Hill ADK., McDermott E., Crow J. 2004. High Preoperative CA 15-3 Concentration Predict Adverse Outcome in Node-Negative and Node-Positive Breast Cancer: Study 600 Patients with Histological Confirmed Breast Cancer. *Clinical Chemistry*, 50 :559-563.
- Ebeling FG., Stieber P., Untch M et al. 2002. Serum CEA and CA 15-3 as Prognostic Factors in Primary Breast Cancer. *British Journal of Cancer*, 86: 1217-22.
- Esteva., Zurrada S. 2005. *Breast Cancer A Practical Guide*, 3rd ed. Elsevier Saunders, Philadelphia: 15-53.
- Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S., & Amir, E. (2017). Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis. *Breast Cancer Research*, 19(1), 1–13. <https://doi.org/10.1186/s13058-016-0794-1>
- Fan S., Xie X., Shen Y., Wang W., Gu X., Yao Z. 2022. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study. *Medicine*. 101(32): 1-7.
- Globocan, International Agency for Research on Cancer (IARC). 2020. Estimated Cancer Incidence Mortality and Prevalence in Indonesia. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>.
- Gonzalez-Angulo AM., CM Strom EA., Buzdar AU., Kau SW., Broglio KR, 2004. Central Nervous System Metastases in Patients With High-Breast Carcinoma After Multimodality Treatment. *Cancer*, 101: 1766.



- Gradishar WJ, Anderson BO, Balassanian R, et al. 2018. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 16(3):310-320.
- Greene FL., Page DL., Fleming ID., Fritz AG., Balch CM., Haller DG. 2010. *The AJCC Cancer Staging Manual 7 th Edition*. New York.
- Handy B. 2009. The Clinical utility of Tumor Marker. *Lab Medicine*, 40 (2): 103.
- Inoue, Y., Fujishima, M., Ono, M., Masuda, J., Ozaki, Y., Maeda, T., Uehiro, N., Takahashi, Y., Kobayashi, T., Sakai, T., Osako, T., Ueno, T., & Ohno, S. (2022). Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer. *Breast Cancer Research and Treatment*, 196(2), 341–348. <https://doi.org/10.1007/s10549-022-06726-w>
- Ivars Rubio, A., Yufera, J. C., de la Morena, P., Fernández Sánchez, A., Navarro Manzano, E., García Garre, E., García Martínez, E., Marín Zafra, G., Sánchez Cánovas, M., García Torralba, E., & Ayala de la Peña, F. (2019). Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables. *Scientific Reports*, 9(1), 1–9. <https://doi.org/10.1038/s41598-019-53606-3>
- Jennifer J Rahn., Jing Zhang., Qiang Shen. 2008. *Molecular Cancer Research: MUC1 Initiates Src-CrkL-Rac1/Cdc42-Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1*, 6: 555-567.
- Kabel AM. 2017. Tumor Markers of Breast Cancer: New Prospectives. *Journal of Oncological Sciences*, 3:5-11
- Keyhani M., Nasizadeh S., Dehghannejad A. 2005. Serum CA 15-3 Measurement in Breast Cancer Patients Before and After Mastectomy. *Archives of Iranian Medicine*, 8(4): 263-66.



Alisa, Rizka, Aulia. 2022. Overview of Metastasis Location in Breast Cancer patients based on Histopathological type and grading in Cut

- Meutia General Hospital Lhokseumawe in 2020-2021. *Indonesian J of Medical*, 2(4).
- Kmietowicz, Z. 1998. *Patients With Bone Metastases Need Better Care*. BMJ Books.
- Kurnia A. 2010. *Keajaiban payudara 4th ed*. Jakarta : FKUI/RSCM.
- Kurniati RW. 2004. *Penampilan Diagnostik Cancer Antigen 15-3 (CA 15-3) pada Penderita Kanker Payudara di RS. Dr. Sardjito Yogyakarta: Kajian pada Stadium Dini dan Stadium Lanjut. Fakultas Kedokteran Universitas Gadjah Mada Yogyakarta*.
- Laessig D., Dorothea N., Heinemann V., Untch M., Kahlert S., Bauerfeind. 2007. Importance of CEA and CA 15-3 during Disease Progression in Metastatic Breast Cancer Patients. *Anticancer Research*, 27, 1963-1968.
- Lecouvet FE, Talbot JN, Messiou C, et al. 2014. EORTC Imaging Group. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. *Eur J Cancer*, 50(15):2519-31.
- Liedtke C, Kolberg HC. 2016. Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts. *Breast Care (Basel)*;11(4):275-281.
- Lin NU., B.J Winer EP. 2004. CNS Metastases in Breast Cancer. *J Clin Oncol*, 22: 3608-3617.
- Lou, C., Jin, F., Zhao, Q., & Qi, H. (2022). Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer. *American Journal of Translational Research*, 14(5), 3240–3246.
- Lumachi F., Basso SM., Brandes AA. *Relationship between Tumor Markers CEA and CA 15-3, TNM staging, Esterogen Receptor Rate and MIB-1 in Patients with pT1-2 Breast Cancer. In: Anticancer Resp*, 24(5B): 4.



- MacEwan JP., Doctor J., Mulligan K., May SG., Batt K., Zacker C. 2019. The Value of Progression-Free Survival in Metastatic Breast Cancer : Result From a Survey of Patients and Providers. *MDM Policy and Practice*, 1-14.
- Mahendar P., Nalini Y., Nagulu M. 2011. Evaluation of Tumor Markers in Southern Indian Breast Cancer Patients. *Asian Pascific J Cancer P Prev*: 157-159.
- Manuaba TW. 2010. *Panduan Penatalaksanaan Kanker Payudara. Panduan Penatalaksanaan Kanker Solid Peraboi 2010*. Jakarta: Sagung Seto.
- Mintian, Y., Wang, Y. 2013. *Karsinoma Mamae dalam Buku Ajar Onkologi Klinis Edisi 2*. Jakarta : Fakultas Kedokteran Universitas Indonesia.
- Mutebi M, Anderson BO, Duggan C, et al. 2020. Breast cancer treatment: A phased approach to implementation. *Cancer*;126 Suppl 10:2365- 2378.
- Nam, S. eun, Lim, W., Jeong, J., Lee, S., Choi, J., Park, H. K., Jung, Y. S., Jung, S. P., & Bae, S. Y. (2019). The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. *Breast Cancer Research and Treatment*, 177(3), 669–678. <https://doi.org/10.1007/s10549-019-05357-y>
- Orditura, M., Galizia, G., Diana, A., Saccone, C., Cobellis, L., Ventriglia, J., Iovino, F., Romano, C., Morgillo, F., Mosca, L., Diadema, M. R., Lieto, E., Procaccini, E., De Vita, F., & Ciardiello, F. (2016). Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis. *ESMO Open*, 1(2), 1–9. <https://doi.org/10.1136/esmoopen-2016-000038>
- Pesapane F, Downey K, Rotili A, Cassano E, Koh DM. 2020. Imaging diagnosis of metastatic breast cancer. *Insights Imaging*. 2020;11(1):79.



o E. 2004. *Signifikansi dari Korelasi Uji Petanda Tumor CEA, CA dengan Sidik Tulang pada Pasien Kanker Payudara*. Bagian Ilmu Kteran Nuklir FK Universitas Padjajaran Bandung.

- Rakha EA., Reis-Filho JS., Baehner F., Dabbs., DJ., Decker T. 2010. Breast Cancer Prognostic Classification in the Molecular Era : The Role of Histological Grade. *Breast Cancer Research*, 12(4): 207. <https://doi.org/10.1186/bcr2607>
- S Bafna., S Kaur., SK Batra. 2010. Membrane-bound Mucins: The Mechanistic Basis for Alterations in the Growth and Survival of Cancer Cell. *Oncogene*, 29: 2893-2904.
- Sacher RA., McPherson RA. 2004. Petanda tumor Tinjauan Klinis Hasil Pemeriksaan Laboratorium, Ed.11. Jakarta : EGC.
- Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, Song J, Vahdat L. 2015. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. *Springerplus*, 4:532.
- San,Gang Wu., Zhen Yu He., Juan Zhou., Jia Yuan Sun., Feng Yan Li., Qin lin. 2014. Serum Levels of CEA and CA 15-3 in Different Molecular Subtypes and Prognostic Value in Chinese Breast Cancer. *The Breast Original Article*, 23: 88-93.
- Suega K., Bakta IM. 2006. Penanda tumor dan Aplikasi klinik. In: SudoyoAW, Setyohadi dkk ed. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta : Pusat Penerbitan Ilmu penyakit Dalam FKUI.
- Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I and Di Gioia D. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients. *Clin Chim Acta* 2015; 448: 228-31.
- Sung H., Ferlay J., Siegel R et al. 2021. Global Cancer Statistics 2020 : Globocan Estimates of Incidence and Mortality Worldwide for 36 cancer in 185 countries. *Cancer J Clinicians*, 7(13) : 209-249.



- A, Khan SA, Chrischilles EA, Schroeder MC. 2016. Initial surgery survival in stage IV breast cancer in the United States, 1988-2011. *J Surg Oncol* ;151(5):424-31.

- Tosello G, Torloni MR, Mota BS, Neeman T, Riera R. 2018. Breast surgery for metastatic breast cancer. *Cochrane Database Syst Rev*; 3(3): CD011276.
- Uehara M., Kinoshita T., Hojo T. 2008. Long-term prognostic study of Carcinoembrionic Antigen (CEA) and Carbohydrate Antigen 15-3 (CA 15-3) in breast cancer. *Int J Clin Oncol*, 13: 447-451.
- Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X and Jing J. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA153, and TPS in metastatic breast cancer. *Clin Chim Acta* 2017; 470: 51-55.
- Wulandari D. 2007. Perkembangan Pemeriksaan Penanda Tumor Terkini pada Kanker Payudara in : Oesman F, ed. Jakarta : Pendidikan Berkesinambungan Patologi Klinik Departemen Patologi Klinik FKUH.
- Yanagawa M. Ikemot K., Kawauchi S., Furuya T., Yamamoto S., Oka M. 2012. Luminal A and luminal B (HER-2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. *BMC Research Notes*, 5(376): 1-8.
- Yang Y., Zhang H., Zhang M., Meng Q., Cai L., Zhang Q. (2017). Elevation of Serum CEA and CA 15-3 Levels during Antitumor Therapy Predicts Poor Therapeutic Response in Advanced Breast Cancer Patients. *Oncology Letters*, 14, 7549-7556.
- Yulianto, R. Korelasi Kadar Her-2 Serum dengan Status Her-2 Jaringan Pada Penderita Kanker Payudara Stadium Lanjut Lokal dan Stadium Metastasis di Makassar, 2013.



LAMPIRAN

No. RM	JK	Umur	CEA	CA-15-3	Neutrofil	Limfosit	NLR Ratio	Metastasis	PFS (bulan)
9078	P	62	5.82	9.3	60.8	25.4	2.393700787	Tidak ada	19
48826	P	49	27.31	38.11	67.7	26.1	2.593869732	Paru, Tulang	16
111924	P	49	1.05	13.13	52.9	33.1	1.598187311	Tidak ada	19
205581	P	69	2.31	6.84	69	20.9	3.301435407	Otak	9
259949	P	64	1.86	377.55	34.1	57.1	0.597197898	KGB	10
277755	P	48	2.56	91.65	59.9	31.9	1.877742947	Tidak ada	8
427566	P	54	78.57	430	56.5	32	1.765625	Tulang	15
536574	P	71	1.48	8.13	55.5	32.6	1.702453988	Tidak ada	20
588907	P	51	2.32	24.26	79.1	17.3	4.572254335	Tulang	16
596472	P	38	0.3	10.74	54.2	30.6	1.77124183	Tidak ada	24
652448	P	51	5.97	111.7	55.6	38.5	1.444155844	Tidak ada	8
656342	P	49	2.22	21.3	57.9	33.2	1.743975904	Paru, Tulang, Hepar	3
661300	P	46	1.07	53.84	49.4	38	1.3	Tidak ada	14
692505	P	46	2.38	20.16	47.5	37.8	1.256613757	Tidak ada	18
692616	P	51	112.29	125.4	60.1	27	2.225925926	Tulang	14
693850	P	52	1.47	6.24	48.7	41.6	1.170673077	Tulang, Hepar	12
697150	P	41	1.54	17.71	47.7	44.6	1.069506726	Tidak ada	23
700904	P	58	0.63	13.58	48.1	39.2	1.227040816	Tidak ada	19
733116	P	50	2.27	125.6	61.3	31.5	1.946031746	Tidak ada	9
751862	P	59	0.66	4.9	62.9	26.4	2.382575758	Tidak ada	17
	P	46	1	9.87	53.7	37.9	1.416886544	Tidak ada	20
	P	53	9.36	6.59	67.7	21.5	3.148837209	Otak	2



796864	P	38	226	363.2	54.7	37	1.478378378	Tulang, Paru, Hepar	8
798287	P	56	0.1	4.51	51.4	41.5	1.238554217	Tidak ada	20
799715	P	44	3.61	17.15	65.1	27.2	2.393382353	Tulang	11
801370	P	56	3.43	21.47	72.3	19.5	3.707692308	Tidak ada	21
803016	P	52	0.65	16.35	59.5	31.4	1.894904459	Tidak ada	21
806313	P	48	2.9	7.8	51.7	34.5	1.498550725	Tidak ada	18
806909	P	41	29.34	79.24	47.2	42.8	1.102803738	Tulang	16
812430	P	56	1.35	28.02	67.4	26.1	2.582375479	Paru, Tulang, Otak	9
821268	P	50	1.05	23.05	46.9	46.9	1	Tidak ada	22
831108	P	45	1.34	4.69	67.1	22.7	2.955947137	Tidak ada	19
833482	P	42	0.69	10.52	58.5	31	1.887096774	Tidak ada	20
836343	P	48	220	38.37	59.1	33	1.790909091	Tidak ada	12
844501	P	37	31.83	105.1	51.2	38.5	1.32987013	Tidak ada	14
854649	P	57	1.25	10.55	74.4	18.2	4.087912088	Tidak ada	21
854897	P	45	1.97	20.99	43.4	43.8	0.99086758	Tulang	15
859075	P	37	0.57	17.3	76	19.9	3.819095477	Paru	6
862806	P	45	52.67	123.18	55.5	35.8	1.55027933	Tidak ada	10
866108	P	42	8.56	58.23	49	42.2	1.161137441	Tulang	13
874167	P	46	88.42	126.83	48.2	29.1	1.656357388	Tulang	13
874569	P	44	139.31	691	71.4	19.4	3.680412371	Tulang	11
878911	P	60	1100	25.56	65.2	23.6	2.762711864	Tulang, Hepar	10
879893	P	43	1.39	8.24	69.7	23.1	3.017316017	Tulang	15
	P	47	43.4	157.56	72.6	21.2	3.424528302	hepar	14
	P	66	5.37	1012.63	66.3	26	2.55	Tulang	8



882653	P	44	1.34	22.76	58.9	27.7	2.126353791	pleura	14
883522	P	41	1.36	2120	81.8	9.5	8.610526316	Paru, Hepar	6
885142	P	51	43.57	332.73	85.2	8.3	10.26506024	Tulang, Paru	13
890792	P	41	3.95	14.14	56.1	38.8	1.445876289	Otak	10
891503	P	32	1.09	10.82	62.6	34	1.841176471	Tulang, hepar, otak	10
891882	P	55	0.68	17.77	67.1	22.8	2.942982456	Tidak ada	23
893082	P	51	2.46	20.36	52.7	33.3	1.582582583	Paru	15
895551	P	53	1.49	22.7	66.4	21.4	3.102803738	Tidak ada	19
896449	P	46	33.5	15.03	55.3	31.8	1.738993711	Otak	15
899457	P	42	4.77	4.51	55.6	33.1	1.679758308	Tidak ada	18
900795	P	49	0.75	55.52	73.7	13.7	5.379562044	Tulang	5
902210	P	48	1.09	18.79	44.7	44.9	0.995545657	Tidak ada	22
902837	P	55	1.16	18.44	37	48	0.770833333	Tidak ada	24
903932	P	45	0.84	37.6	53.3	33.1	1.610271903	Otak	10
904120	P	53	1.03	9	63.8	29.8	2.140939597	Tidak ada	22
904605	P	56	1.2	19.11	60.6	24.6	2.463414634	Tidak ada	18
904784	P	44	6.1	11.23	58	35.5	1.633802817	Tidak ada	20
906383	P	47	95.63	7.54	61.4	27.8	2.208633094	Hepar	13
906761	P	52	75.55	396.68	81.1	12.7	6.385826772	Tulang	14
907068	P	49	2.28	18.91	59.9	32.9	1.820668693	Tidak ada	20
907385	P	25	0.91	19.66	74.2	18.5	4.010810811	Tidak ada	19
907395	P	47	4.07	17.08	61.7	32.1	1.92211838	Tidak ada	19
	P	52	2.16	16.59	58.1	30.6	1.89869281	Tidak ada	19
	P	31	6.34	19.1	70.5	18.8	3.75	Tidak ada	19



907704	P	43	0.71	11.72	71.4	18.6	3.838709677	Tidak ada	19
908170	P	48	6.6	26.13	63.6	27.6	2.304347826	Tidak ada	12
908306	P	54	2.43	12.49	55.3	30.3	1.825082508	Tidak ada	21
908629	P	36	0.2	15.77	44	45.5	0.967032967	Tidak ada	22
908994	P	57	9.09	19.36	64.6	26.9	2.401486989	hepar	4
909110	P	55	85.98	53.88	33.6	60	0.56	Paru	15
909123	P	44	1.07	21.3	44.4	42.2	1.052132701	KGB	19
909382	P	58	0.9	13.04	37.9	54.5	0.695412844	Hepar	13
909897	P	43	1.39	35.89	57.7	32.5	1.775384615	Tulang	12
910067	P	48	0.77	5.42	52.9	33.9	1.560471976	Hepar	11
910194	P	46	1.14	11.4	56.6	29.7	1.905723906	Tidak ada	18
910319	L	71	3.07	22.38	64.4	26.3	2.448669202	Paru	15
910337	P	33	0.4	12.52	71.6	22.8	3.140350877	Tidak ada	21
911015	P	28	9.72	8.1	49.7	41	1.212195122	Tidak ada	17
911366	P	63	62.09	49.11	63.6	25.5	2.494117647	Paru	13
911398	P	42	2.55	12.98	56.7	30.9	1.834951456	Tidak ada	17
911477	P	41	2.32	24.06	50.6	37.4	1.352941176	Tidak ada	19
911644	P	35	1.08	17.67	47.8	37.2	1.284946237	Paru	17
912612	P	32	1.17	16.74	64.1	24.5	2.616326531	Paru, Tulang	16
913558	P	49	1.09	45.74	52.9	39.4	1.342639594	Tulang	13
914470	P	50	123.43	12.14	58	32.1	1.806853583	Hepar	13
915573	P	49	1.58	6.9	55.7	32.6	1.708588957	KGB	18
	P	48	3.91	12.64	57.2	33.1	1.728096677	Tidak ada	18
	P	42	213	274.5	72.1	18.2	3.961538462	Tulang, Paru	9



918969	P	44	20.17	119.82	23.4	47	0.49787234	Tulang, Paru	17
920736	P	58	52.3	21.01	46.3	42.3	1.094562648	Paru	11
921085	P	34	1.53	26.14	66.3	22	3.013636364	Tidak ada	13
923214	P	65	18.33	27.27	48.3	38.5	1.254545455	Tulang, Hepar	18
924203	P	49	1.16	24.52	45.2	44.6	1.013452915	KGB	18
924507	P	53	1.92	13.94	68.8	25.5	2.698039216	Tidak ada	17
924762	P	41	1.87	20	47.2	43.6	1.082568807	Hepar	14
924774	P	57	1.02	16.77	67.8	22.2	3.054054054	Tidak ada	18
924789	P	39	1.33	39.84	67.6	22.6	2.991150442	Tidak ada	12
925237	P	43	0.67	10.3	59.6	30.1	1.980066445	Tidak ada	22
925242	P	53	1.36	29.38	59	28.9	2.041522491	Tidak ada	18
925341	P	29	0.77	23.57	48.3	38.1	1.267716535	Tidak ada	21
925567	P	63	0.5	15.16	51	40.3	1.265508685	Tidak ada	22
925611	P	51	1.62	24.17	64.3	24.7	2.603238866	Tulang	17
925937	P	37	1.16	29.98	67.91	16.2	4.191975309	Tidak ada	11
925952	P	57	2.64	28.45	66.9	26.2	2.553435115	Tidak ada	16
926048	P	66	8.3	15.95	51.8	34	1.523529412	Tidak ada	22
926701	P	48	1.68	23.05	59.8	33.2	1.801204819	Tulang, Hepar	15
927854	P	49	6.99	84.8	82.2	11.3	7.274336283	Tidak ada	10
928035	P	50	0.5	5.4	64.6	30.5	2.118032787	Tidak ada	17
929857	P	50	0.69	15.64	74.2	18.8	3.946808511	Otak	11
930530	P	52	0.7	31.45	47.3	32.5	1.455384615	Tidak ada	16
	P	38	0.91	6.28	65.9	27.5	2.396363636	Otak	11
	P	35	1.85	9.99	58.5	35	1.671428571	Tidak ada	21



931428	P	51	5.06	11.5	52.6	39.6	1.328282828	Tidak ada	18
931571	P	38	2.47	12.71	66	26	2.538461538	Tidak ada	19
931589	P	58	5.93	8.97	80.2	15.4	5.207792208	Tidak ada	21
931727	P	30	5.44	22.03	81.3	11.2	7.258928571	Hepar	14
931980	P	38	4.6	21.32	51	40.9	1.246943765	Tidak ada	22
931991	P	39	0.5	31.8	69.1	21.9	3.155251142	Tidak ada	15
932099	P	61	1.73	10.43	74.6	18.9	3.947089947	Tidak ada	21
932457	P	35	1.32	9	52.7	42.1	1.251781473	Tidak ada	23
932873	P	60	1.24	37.36	71.8	20.1	3.572139303	Tidak ada	14
933476	P	54	9.82	19.5	55.9	32.1	1.741433022	Tidak ada	20
934186	P	52	2.76	12.74	52.1	36.5	1.42739726	Tidak ada	17
934237	P	63	4.2	43.41	61.9	28.9	2.141868512	Tidak ada	12
934378	P	55	96.48	672	42.5	42.6	0.997652582	Tidak ada	18
934768	P	66	1.87	15.28	32.7	53.9	0.606679035	Tidak ada	24
935247	P	48	1.97	11.8	64.3	27	2.381481481	Tidak ada	20
935820	P	49	0.2	10.18	70.2	19.5	3.6	Tidak ada	18
936275	P	41	0.75	13.89	64.2	15.7	4.089171975	Tidak ada	18
936475	P	46	1.54	5.41	77	13.6	5.661764706	Tidak ada	18
937506	P	48	1.26	14.04	63	28.9	2.179930796	Tulang	14
938769	P	43	1.74	14.7	65.9	26.5	2.486792453	Tidak ada	19
939178	P	61	1.42	14.7	46.8	38.6	1.212435233	Tidak ada	18
939208	P	41	1.33	9.12	65.9	29.3	2.249146758	Tidak ada	24
	P	38	31.14	41.7	67.3	24.5	2.746938776	Tidak ada	13
	P	41	29.6	540	61.6	34.7	1.775216138	Tulang	15



941695	P	31	54.65	16.8	45.9	43.7	1.050343249	Tulang	12
942263	P	48	2.53	5.95	61.5	29.7	2.070707071	Hepar	12
943305	P	61	0.68	13.1	77.1	18	4.283333333	Tidak ada	16
943325	P	37	0.97	140.19	50.6	37.8	1.338624339	Hepar	10
943619	P	44	1.41	20.91	43.6	39.7	1.098236776	Tidak ada	17
945535	P	58	2.75	7.71	58.1	26.5	2.19245283	Tidak ada	18
945626	P	60	2.34	21.81	51.1	40.6	1.25862069	Tidak ada	20
945785	P	53	0.79	12.96	42.5	51.4	0.826848249	Hepar	12
946737	P	54	9.71	23	93.1	2.2	42.31818182	Tulang, Paru	15
947440	P	52	89.5	492	64.6	20.9	3.090909091	Tulang, Hepar	12
947560	P	64	2.06	23.71	67.4	24.4	2.762295082	Tidak ada	20
947975	P	58	0.68	7.68	46.7	33.2	1.406626506	Tidak ada	19
948607	P	39	1.97	11.64	62.1	30.3	2.04950495	Tidak ada	17
951272	P	44	3.83	16.45	43.4	34.1	1.272727273	Tidak ada	20
953658	P	47	0.64	21.13	61.8	30.5	2.026229508	Tidak ada	20
956113	P	52	1.12	13.96	55.9	29	1.927586207	Tidak ada	16
957390	P	34	0.3	13.23	68.9	24.5	2.812244898	Tidak ada	20

